High Sensitivity Cardiac Troponin T in Patients With Atrial Fibrillation Admitted to an Emergency Department (ED)

September 2, 2015 updated by: Professor Hugo Katus, University Hospital Heidelberg
The purpose of this study was to collect data on the prevalence and clinical significance of elevated cardiac troponin in a large registry of unselected patients with atrial fibrillation presenting to an emergency department.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

3037

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

A cohort of approximately 3,500 consecutive patients presenting to the emergency department of the University Clinic Heidelberg between June 2009 and March 2013.

Description

Inclusion Criteria:

  • documented atrial fibrillation in admission EKG or diagnosis of atrial fibrillation at admission.

Exclusion Criteria:

  • no patients are excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
vascular and non-vascular death
Time Frame: up to 60 months
Assessment via review of inpatient- and outpatient visit reports, patient phone calls, postal queries with standardised questionnaires, contact with primary care physicians and resident registration office inquiries.
up to 60 months
nonfatal myocardial infarction
Time Frame: up to 60 months
Assessment via review of inpatient- and outpatient visit reports, patient phone calls, postal queries with standardised questionnaires, contact with primary care physicians and resident registration office inquiries.
up to 60 months
stroke/transitory ischemic attack (TIA)
Time Frame: up to 60 months
Assessment via review of inpatient- and outpatient visit reports, patient phone calls, postal queries with standardised questionnaires, contact with primary care physicians and resident registration office inquiries.
up to 60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital Heidelberg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

July 1, 2015

Study Completion (Actual)

July 1, 2015

Study Registration Dates

First Submitted

August 6, 2015

First Submitted That Met QC Criteria

September 2, 2015

First Posted (Estimate)

September 4, 2015

Study Record Updates

Last Update Posted (Estimate)

September 4, 2015

Last Update Submitted That Met QC Criteria

September 2, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • S-377-2013

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe